Small molecule and gene therapy treatments for lysosomal storage disorders, repurposed drugs
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
39
NCT04637282
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
Phase: Phase 3
Role: Lead Sponsor
Start: Mar 1, 2026
Completion: Mar 31, 2026
Loading map...